Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment

 

 Permissions and Reprints

Abstract

Interstitial lung disease (ILD) is a common pulmonary complication of rheumatoid arthritis (RA), causing significant morbidity and mortality. Optimal treatment for RA-ILD is not yet well defined. Reliable prognostic indicators are largely byproducts of prior ILD progression, including low or decreasing forced vital capacity and extensive or worsening fibrosis on imaging. In the absence of validated tools to predict treatment response, decisions about whether to initiate or augment treatment are instead based on clinical judgment. In general, treatment should be initiated in patients who are symptomatic, progressing, or at high risk of poor outcomes. Retrospective data suggest that mycophenolate mofetil, azathioprine, and rituximab are likely effective therapies for RA-ILD. Abatacept is also emerging as a potential first-line treatment option for patients with RA-ILD. Further, recent data demonstrate that immunosuppression may be beneficial even in patients with a usual interstitial pneumonia (UIP) pattern on imaging, suggesting that immunosuppression should be considered irrespective of imaging pattern. Recent randomized controlled trials have shown that antifibrotic medications, such as nintedanib and likely pirfenidone, slow forced vital capacity decline in RA-ILD. Consideration can be given to antifibrotic initiation in patients progressing despite immunosuppression, particularly in patients with a UIP pattern. Future research directions include developing tools to predict which patients will remain stable from patients who will progress, discriminating patients who will respond to treatment from nonresponders, and developing algorithms for starting immunosuppression, antifibrotics, or both as first-line therapies.

Publication History

Article published online:
14 March 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Safiri S, Kolahi AA, Hoy D. et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis 2019; 78 (11) 1463-1471
  CrossrefPubMedGoogle Scholar
• 2 Black RJ, Lester S, Tieu J. et al. Mortality estimates and excess mortality in rheumatoid arthritis. Rheumatology (Oxford) 2023; 62 (11) 3576-3583
  CrossrefPubMedGoogle Scholar
• 3 Olson AL, Swigris JJ, Sprunger DB. et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011; 183 (03) 372-378
  CrossrefPubMedGoogle Scholar
• 4 England BR, Sayles H, Michaud K. et al. Cause-specific mortality in male US Veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016; 68 (01) 36-45
  CrossrefPubMedGoogle Scholar
• 5 Hayakawa H, Sato A, Imokawa S, Toyoshima M, Chida K, Iwata M. Bronchiolar disease in rheumatoid arthritis. Am J Respir Crit Care Med 1996; 154 (05) 1531-1536
  CrossrefPubMedGoogle Scholar
• 6 Devouassoux G, Cottin V, Lioté H. et al; Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM“O”P). Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J 2009; 33 (05) 1053-1061
  CrossrefPubMedGoogle Scholar
• 7 Lin E, Limper AH, Moua T. Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series. BMC Pulm Med 2018; 18 (01) 105
  CrossrefPubMedGoogle Scholar
• 8 Duarte AC, Porter J, Leandro MJ. Bronchiectasis in rheumatoid arthritis. A clinical appraisial. Joint Bone Spine 2020; 87 (05) 419-424
  CrossrefPubMedGoogle Scholar
• 9 Kamanli A, Gok U, Sahin S, Kaygusuz I, Ardicoglu O, Yalcin S. Bilateral cricoarytenoid joint involvement in rheumatoid arthritis: a case report. Rheumatology (Oxford) 2001; 40 (05) 593-594
  CrossrefPubMedGoogle Scholar
• 10 Koslow M, Young JR, Yi ES. et al. Rheumatoid pulmonary nodules: clinical and imaging features compared with malignancy. Eur Radiol 2019; 29 (04) 1684-1692
  CrossrefPubMedGoogle Scholar
• 11 Makol A, Matteson EL, Warrington KJ. Rheumatoid vasculitis: an update. Curr Opin Rheumatol 2015; 27 (01) 63-70
  CrossrefPubMedGoogle Scholar
• 12 Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum 2006; 35 (06) 368-378
  CrossrefPubMedGoogle Scholar
• 13 Brown KK, Roger S. Rheumatoid lung disease. Proc Am Thorac Soc 2007; 4 (05) 443-448
  CrossrefPubMedGoogle Scholar
• 14 Bongartz T, Nannini C, Medina-Velasquez YF. et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010; 62 (06) 1583-1591
  CrossrefPubMedGoogle Scholar
• 15 Solomon JJ, Danoff SK, Woodhead FA. et al; TRAIL1 Network Investigators. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med 2023; 11 (01) 87-96
  CrossrefPubMedGoogle Scholar
• 16 Matson SM, Baqir M, Moua T. et al. Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory. Chest 2023; 163 (04) 861-869
  CrossrefPubMedGoogle Scholar
• 17 Marcoux V, Lok S, Mondal P. et al. Treatment of rheumatoid arthritis-associated interstitial lung disease in a multi-center registry cohort. J Thorac Dis 2023; 15 (05) 2517-2527
  CrossrefPubMedGoogle Scholar
• 18 Cavagna L, Monti S, Grosso V. et al. The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. BioMed Res Int 2013; 2013: 759760
  CrossrefPubMedGoogle Scholar
• 19 Myasoedova E, Crowson CS, Turesson C, Gabriel SE, Matteson EL. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. J Rheumatol 2011; 38 (06) 983-989
  CrossrefPubMedGoogle Scholar
• 20 Hyldgaard C, Hilberg O, Pedersen AB. et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 2017; 76 (10) 1700-1706
  CrossrefPubMedGoogle Scholar
• 21 Sparks JA, Jin Y, Cho SK. et al. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology (Oxford) 2021; 60 (08) 3689-3698
  CrossrefPubMedGoogle Scholar
• 22 Raimundo K, Solomon JJ, Olson AL. et al. Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality. J Rheumatol 2019; 46 (04) 360-369
  CrossrefPubMedGoogle Scholar
• 23 Roos Ljungberg K, Joshua V, Skogh T. et al. Secretory anti-citrullinated protein antibodies in serum associate with lung involvement in early rheumatoid arthritis. Rheumatology (Oxford) 2020; 59 (04) 852-859
  CrossrefPubMedGoogle Scholar
• 24 Doyle TJ, Patel AS, Hatabu H. et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med 2015; 191 (12) 1403-1412
  CrossrefPubMedGoogle Scholar
• 25 Kamiya H, Panlaqui OM. Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody. BMJ Open 2021; 11 (03) e040465
  CrossrefPubMedGoogle Scholar
• 26 Kelly CA, Saravanan V, Nisar M. et al; British Rheumatoid Interstitial Lung (BRILL) Network. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics–a large multicentre UK study. Rheumatology (Oxford) 2014; 53 (09) 1676-1682
  CrossrefPubMedGoogle Scholar
• 27 Giles JT, Danoff SK, Sokolove J. et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis 2014; 73 (08) 1487-1494
  CrossrefPubMedGoogle Scholar
• 28 Koduri G, Norton S, Young A. et al; ERAS (Early Rheumatoid Arthritis Study). Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 2010; 49 (08) 1483-1489
  CrossrefPubMedGoogle Scholar
• 29 Juge P-A, Lee JS, Ebstein E. et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med 2018; 379 (23) 2209-2219
  CrossrefPubMedGoogle Scholar
• 30 Juge P-A, Borie R, Kannengiesser C. et al; FREX consortium. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J 2017; 49 (05) 1602314
  CrossrefPubMedGoogle Scholar
• 31 Ghodrati S, Pugashetti JV, Kadoch MA, Ghasemiesfe A, Oldham JM. Diagnostic accuracy of chest radiography for detecting fibrotic interstitial lung disease. Ann Am Thorac Soc 2022; 19 (11) 1934-1937
  CrossrefPubMedGoogle Scholar
• 32 Hoffmann T, Oelzner P, Franz M. et al. Assessing the diagnostic value of a potential screening tool for detecting early interstitial lung disease at the onset of inflammatory rheumatic diseases. Arthritis Res Ther 2022; 24 (01) 107
  CrossrefPubMedGoogle Scholar
• 33 Kass DJ, Nouraie M, Glassberg MK. et al. Comparative profiling of serum protein biomarkers in rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis. Arthritis Rheumatol 2020; 72 (03) 409-419
  CrossrefPubMedGoogle Scholar
• 34 Qin Y, Wang Y, Meng F. et al. Identification of biomarkers by machine learning classifiers to assist diagnose rheumatoid arthritis-associated interstitial lung disease. Arthritis Res Ther 2022; 24 (01) 115
  CrossrefPubMedGoogle Scholar
• 35 Raghu G, Remy-Jardin M, Myers JL. et al; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018; 198 (05) e44-e68
  CrossrefPubMedGoogle Scholar
• 36 Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford) 2017; 56 (03) 344-350
  CrossrefPubMedGoogle Scholar
• 37 Solomon JJ, Chung JH, Cosgrove GP. et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2016; 47 (02) 588-596
  CrossrefPubMedGoogle Scholar
• 38 Brooks R, Baker JF, Yang Y. et al. The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford) 2022; 61 (12) 4667-4677
  CrossrefPubMedGoogle Scholar
• 39 Kelly CA, Nisar M, Arthanari S. et al. Rheumatoid arthritis related interstitial lung disease - improving outcomes over 25 years: a large multicentre UK study. Rheumatology (Oxford) 2021; 60 (04) 1882-1890
  CrossrefPubMedGoogle Scholar
• 40 Jacob J, Hirani N, van Moorsel CHM. et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J 2019; 53 (01) 1800869
  CrossrefPubMedGoogle Scholar
• 41 Kim EJ, Elicker BM, Maldonado F. et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35 (06) 1322-1328
  CrossrefPubMedGoogle Scholar
• 42 Ley B, Ryerson CJ, Vittinghoff E. et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156 (10) 684-691
  CrossrefPubMedGoogle Scholar
• 43 Ryerson CJ, Vittinghoff E, Ley B. et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 2014; 145 (04) 723-728
  CrossrefPubMedGoogle Scholar
• 44 Morisset J, Vittinghoff E, Lee BY. et al. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. Respir Med 2017; 127: 51-56
  CrossrefPubMedGoogle Scholar
• 45 Solomon JJ, Ryu JH, Tazelaar HD. et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med 2013; 107 (08) 1247-1252
  CrossrefPubMedGoogle Scholar
• 46 Kim HC, Lee JS, Lee EY. et al. Risk prediction model in rheumatoid arthritis-associated interstitial lung disease. Respirology 2020; 25 (12) 1257-1264
  CrossrefPubMedGoogle Scholar
• 47 Oh JH, Kim GHJ, Cross G. et al. Automated quantification system predicts survival in rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford) 2022; 61 (12) 4702-4710
  CrossrefPubMedGoogle Scholar
• 48 Pugashetti JV, Adegunsoye A, Wu Z. et al. Validation of proposed criteria for progressive pulmonary fibrosis. Am J Respir Crit Care Med 2023; 207 (01) 69-76
  CrossrefPubMedGoogle Scholar
• 49 Oldham JM, Lee CT, Wu Z. et al. Lung function trajectory in progressive fibrosing interstitial lung disease. Eur Respir J 2022; 59 (06) 2101396
  CrossrefPubMedGoogle Scholar
• 50 Assayag D, Lubin M, Lee JS, King TE, Collard HR, Ryerson CJ. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology 2014; 19 (04) 493-500
  CrossrefPubMedGoogle Scholar
• 51 Tashkin DP, Roth MD, Clements PJ. et al; Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4 (09) 708-719
  CrossrefPubMedGoogle Scholar
• 52 Tashkin DP, Elashoff R, Clements PJ. et al; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354 (25) 2655-2666
  CrossrefPubMedGoogle Scholar
• 53 Song JW, Lee HK, Lee CK. et al. Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30 (02) 103-112
  PubMedGoogle Scholar
• 54 Yamano Y, Taniguchi H, Kondoh Y. et al. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. Respirology 2018; 23 (11) 1041-1048
  CrossrefPubMedGoogle Scholar
• 55 Okada H, Kurasawa K, Yamazaki R. et al. Clinical features of organizing pneumonia associated with rheumatoid arthritis. Mod Rheumatol 2016; 26 (06) 863-868
  CrossrefPubMedGoogle Scholar
• 56 Dixon WG, Abrahamowicz M, Beauchamp M-E. et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012; 71 (07) 1128-1133
  CrossrefPubMedGoogle Scholar
• 57 Laan RF, Buijs WC, Verbeek AL. et al. Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity. Ann Rheum Dis 1993; 52 (01) 21-26
  CrossrefPubMedGoogle Scholar
• 58 Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 2016; 35 (10) 2585-2589
  CrossrefPubMedGoogle Scholar
• 59 Broen JCA, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol 2020; 16 (03) 167-178
  CrossrefPubMedGoogle Scholar
• 60 Fischer A, Brown KK, Du Bois RM. et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40 (05) 640-646
  CrossrefPubMedGoogle Scholar
• 61 Oldham JM, Lee C, Valenzi E. et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med 2016; 121: 117-122
  CrossrefPubMedGoogle Scholar
• 62 Schiff M, Beaulieu A, Scott DL, Rashford M. Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials. Clin Drug Investig 2010; 30 (09) 613-624
  CrossrefPubMedGoogle Scholar
• 63 Suarez-Almazor ME, Spooner C, Belseck E. Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000; (04) CD001461
  PubMedGoogle Scholar
• 64 Cohen MD, Keystone E. Rituximab for rheumatoid arthritis. Rheumatol Ther 2015; 2 (02) 99-111
  CrossrefPubMedGoogle Scholar
• 65 Md Yusof MY, Kabia A, Darby M. et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. Rheumatology (Oxford) 2017; 56 (08) 1348-1357
  CrossrefPubMedGoogle Scholar
• 66 Vadillo C, Nieto MA, Romero-Bueno F. et al. Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry. Rheumatology (Oxford) 2020; 59 (08) 2099-2108
  CrossrefPubMedGoogle Scholar
• 67 Mankikian J, Caille A, Reynaud-Gaubert M. et al; EVER-ILD investigators and the OrphaLung network. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J 2023; 61 (06) 2202071
  CrossrefPubMedGoogle Scholar
• 68 Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2010; 37 (02) 234-245
  CrossrefPubMedGoogle Scholar
• 69 Cassone G, Manfredi A, Atzeni F. et al. Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study. J Clin Med 2020; 9 (01) 277
  CrossrefPubMedGoogle Scholar
• 70 Fernández-Díaz C, Loricera J, Castañeda S. et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients. Semin Arthritis Rheum 2018; 48 (01) 22-27
  CrossrefPubMedGoogle Scholar
• 71 Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R. et al. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review. Autoimmun Rev 2021; 20 (06) 102830
  CrossrefPubMedGoogle Scholar
• 72 Kang EH, Jin Y, Desai RJ, Liu J, Sparks JA, Kim SC. Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: a cohort study. Semin Arthritis Rheum 2020; 50 (03) 401-408
  CrossrefPubMedGoogle Scholar
• 73 Fernández-Díaz C, Castañeda S, Melero-González RB. et al. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology (Oxford) 2020; 59 (12) 3906-3916
  CrossrefPubMedGoogle Scholar
• 74 Kovarsky J. Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases. Semin Arthritis Rheum 1983; 12 (04) 359-372
  CrossrefPubMedGoogle Scholar
• 75 Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Cyclophosphamide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000; (04) CD001157
  PubMedGoogle Scholar
• 76 Nakamura K, Ohbe H, Ikeda K. et al. Intravenous cyclophosphamide in acute exacerbation of rheumatoid arthritis-related interstitial lung disease: a propensity-matched analysis using a nationwide inpatient database. Semin Arthritis Rheum 2021; 51 (05) 977-982
  CrossrefPubMedGoogle Scholar
• 77 Manfredi A, Cassone G, Furini F. et al. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Intern Med J 2020; 50 (09) 1085-1090
  CrossrefPubMedGoogle Scholar
• 78 Tardella M, Di Carlo M, Carotti M, Ceccarelli L, Giovagnoni A, Salaffi F. A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease. Inflammopharmacology 2022; 30 (03) 705-712
  CrossrefPubMedGoogle Scholar
• 79 Richeldi L, du Bois RM, Raghu G. et al; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370 (22) 2071-2082
  CrossrefPubMedGoogle Scholar
• 80 Flaherty KR, Wells AU, Cottin V. et al; INBUILD Trial Investigators. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381 (18) 1718-1727
  CrossrefPubMedGoogle Scholar
• 81 Wells AU, Flaherty KR, Brown KK. et al; INBUILD trial investigators. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; 8 (05) 453-460
  CrossrefPubMedGoogle Scholar
• 82 Distler O, Highland KB, Gahlemann M. et al; SENSCIS Trial Investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019; 380 (26) 2518-2528
  CrossrefPubMedGoogle Scholar
• 83 Noble PW, Albera C, Bradford WZ. et al; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377 (9779) 1760-1769
  CrossrefPubMedGoogle Scholar
• 84 King Jr TE, Bradford WZ, Castro-Bernardini S. et al; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370 (22) 2083-2092
  CrossrefPubMedGoogle Scholar
• 85 Maher TM, Corte TJ, Fischer A. et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2020; 8 (02) 147-157
  CrossrefPubMedGoogle Scholar
• 86 Behr J, Prasse A, Kreuter M. et al; RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; 9 (05) 476-486
  CrossrefPubMedGoogle Scholar
• 87 Smolen JS, Landewé R, Bijlsma J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76 (06) 960-977
  CrossrefPubMedGoogle Scholar
• 88 Singh JA, Saag KG, Bridges Jr SL. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016; 68 (01) 1-26
  CrossrefPubMedGoogle Scholar
• 89 Sathi N, Chikura B, Kaushik VV, Wiswell R, Dawson JK. How common is methotrexate pneumonitis? A large prospective study investigates. Clin Rheumatol 2012; 31 (01) 79-83
  CrossrefPubMedGoogle Scholar
• 90 Kremer JM, Alarcón GS, Weinblatt ME. et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40 (10) 1829-1837
  CrossrefPubMedGoogle Scholar
• 91 Juge P-A, Lee JS, Lau J. et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J 2021; 57 (02) 2000337
  CrossrefPubMedGoogle Scholar
• 92 Kiely P, Busby AD, Nikiphorou E. et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open 2019; 9 (05) e028466
  CrossrefPubMedGoogle Scholar
• 93 Raghu G, Anstrom KJ, King Jr TE, Lasky JA, Martinez FJ, Network IPFCR. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366 (21) 1968-1977
  CrossrefPubMedGoogle Scholar
• 94 Lopez-Olivo MA, Amezaga Urruela M, McGahan L, Pollono EN, Suarez-Almazor ME. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev 2015; 1: CD007356
  PubMedGoogle Scholar
• 95 Kotecha S, Ivulich S, Snell G. Review: immunosuppression for the lung transplant patient. J Thorac Dis 2021; 13 (11) 6628-6644
  CrossrefPubMedGoogle Scholar
• 96 Dowman L, Hill CJ, May A, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2021; 2 (02) CD006322
  PubMedGoogle Scholar
• 97 Bell EC, Cox NS, Goh N. et al. Oxygen therapy for interstitial lung disease: a systematic review. Eur Respir Rev 2017; 26 (143) 160080
  CrossrefPubMedGoogle Scholar
• 98 Lim RK, Humphreys C, Morisset J, Holland AE, Johannson KA. O2 Delphi Collaborators. Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. Eur Respir J 2019; 54 (02) 1900421
  CrossrefPubMedGoogle Scholar
• 99 Yazdani A, Singer LG, Strand V, Gelber AC, Williams L, Mittoo S. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant 2014; 33 (05) 514-520
  CrossrefPubMedGoogle Scholar
• 100 Ruwanpura SM, Thomas BJ, Bardin PG. Pirfenidone: molecular mechanisms and potential clinical applications in lung disease. Am J Respir Cell Mol Biol 2020; 62 (04) 413-422
  CrossrefPubMedGoogle Scholar